Abstract: A method for treating severe heart failure, comprising administering to a patient an effective amount of a benzazepine compound (1): wherein R1 is H or halogen, R2 is OH, or —NR5R6 (R5 and R6 are H or lower alkyl, R3 is H, halogen, lower alkyl, or lower alkoxy, R4 is halogen, lower alkyl or lower alkoxy, or a salt thereof, and a pharmaceutical composition containing the benzazepine compound (1) or a salt thereof and use of the compound (1) or a salt thereof for preparing a medicament for treatment of severe heart failure.

Abstract: A method for treating severe heart failure, comprising administering to a patient an effective amount of a benzazepine compound (1): wherein R1 is H or halogen, R2 is OH, or —NR5R6 (R5 and R6 are H or lower alkyl, R3 is H, halogen, lower alkyl, or lower alkoxy, R4 is halogen, lower alkyl or lower alkoxy, or a salt thereof, and a pharmaceutical composition containing the benzazepine compound (1) or a salt thereof and use of the compound (1) or a salt thereof for preparing a medicament for treatment of severe heart failure

Abstract: A method for treating severe heart failure, comprising administering to a patient an effective amount of a benzazepine compound (1): wherein R1 is H or halogen, R2 is OH, or —NR5R6 (R5 and R6 are H or lower alkyl, R3 is H, halogen, lower alkyl, or lower alkoxy, R4 is halogen, lower alkyl or lower alkoxy, or a salt thereof, and a pharmaceutical composition containing the benzazepine compound (1) or a salt thereof and use of the compound (1) or a salt thereof for preparing a medicament for treatment of severe heart failure.

Abstract: A method for treating severe heart failure, comprising administering to a patient an effective amount of a benzazepine compound (1): wherein R1 is H or halogen, R2 is OH, or —NR5R6 (R5 and R6 are H or lower alkyl, R3 is H, halogen, lower alkyl, or lower alkoxy, R4 is halogen, lower alkyl or lower alkoxy, or a salt thereof, and a pharmaceutical composition containing the benzazepine compound (1) or a salt thereof and use of the compound (1) or a salt thereof for preparing a medicament for treatment of severe heart failure.

Abstract: The invention relates to an equipment for preventing an audio apparatus being locked, when it becomes impossible to read in TOC information because of a fault or faults in a disk or an equipment for reproducing the disk. A security equipment for audio apparatus which releases a security operation based on a result of a comparison between a read in TOC information and a previously stored TOC information, the security equipment stopping a judgement on the TOC information when a failure is detected in the disk or the equipment for reproducing the disk (R1-4) at the time of reading in the TOC information. Thereby, the audio apparatus is not locked when the TOC information is read in, because the TOC information which was read in (R5) without a mechanical error, is correct.

Abstract: An agent for prophylaxis or treatment of cataract, which comprises as an active ingredient at least one compound selected from a group consisting of a carbostyril compound of the formula: ##STR1## wherein R.sup.1 is a lower alkanoylamino-substituted lower alkoxy group, and the bond between the 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt thereof, 5-dimethylamino-1-?4-(2-methylbenzoylamino)benzoyl!-2,3,4,5-tetrahydro-1H- benzazepine and 5-hydroxy-7-chloro-1-?2-methyl-4-(2-methylbenzoylamino)benzoyl!-2,3,4,5-te trahydro-1H-benzazepine, a method for prophylaxis or treatment of cataract using the same.